311 related articles for article (PubMed ID: 30053080)
1. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
2. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer.
Paladino S; Melillo RM
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053081
[No Abstract] [Full Text] [Related]
4. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
5. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
6. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
7. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
Cai X; Wang R; Tan J; Meng Z; Li N
Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
[TBL] [Abstract][Full Text] [Related]
9. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
11. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
[TBL] [Abstract][Full Text] [Related]
12. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
14. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
16. The role of miR-139-5p in radioiodine-resistant thyroid cancer.
Pecce V; Sponziello M; Verrienti A; Grani G; Abballe L; Bini S; Annunziata S; Perotti G; Salvatori M; Zagaria L; Maggisano V; Russo D; Filetti S; Durante C
J Endocrinol Invest; 2023 Oct; 46(10):2079-2093. PubMed ID: 36933170
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
